These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17047431)

  • 1. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
    Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
    Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
    Sagar M; Tybring G; Dahl ML; Bertilsson L; Seensalu R
    Gastroenterology; 2000 Sep; 119(3):670-6. PubMed ID: 10982760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
    Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
    Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
    Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intragastric acidity during administration of generic omeprazole or esomeprazole - a randomised, two-way crossover study including CYP2C19 genotyping.
    Miehlke S; Löbe S; Madisch A; Kuhlisch E; Laass M; Grossmann D; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2011 Feb; 33(4):471-6. PubMed ID: 21175704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
    Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
    Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
    Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.
    Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L
    Scand J Gastroenterol; 1998 Oct; 33(10):1034-8. PubMed ID: 9829356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
    Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
    J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
    Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
    Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
    Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
    Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
    Furuta T; Sugimoto M; Shirai N; Ishizaki T
    Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.